Salix Pharmaceuticals Ltd. (SLXP) Reports Mixed Q4 Results; Guides Q1, FY11
Tweet Send to a Friend
Salix Pharmaceuticals Ltd. (NASDAQ: SLXP) reported Q4 EPS of $0.66, $0.16 better than ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
